These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30663547)

  • 1. Acute kidney injury: an unusual complication of posaconazole use.
    Otu A; Bongomin F; Kosmidis C; Denning DW
    J Chemother; 2018; 30(6-8):380-383. PubMed ID: 30663547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole: a broad-spectrum triazole antifungal.
    Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
    Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral neuropathy in patients on long-term triazole antifungal therapy.
    Baxter CG; Marshall A; Roberts M; Felton TW; Denning DW
    J Antimicrob Chemother; 2011 Sep; 66(9):2136-9. PubMed ID: 21685202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.
    Herbrecht R
    Int J Clin Pract; 2004 Jun; 58(6):612-24. PubMed ID: 15311563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
    Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.
    Mello E; Posteraro B; Vella A; De Carolis E; Torelli R; D'Inzeo T; Verweij PE; Sanguinetti M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2017 Jul; 72(7):2089-2092. PubMed ID: 28369489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole: when and how? The clinician's view.
    Katragkou A; Tsikopoulou F; Roilides E; Zaoutis TE
    Mycoses; 2012 Mar; 55(2):110-22. PubMed ID: 21762211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole: a next-generation triazole antifungal.
    Farowski F; Vehreschild JJ; Cornely OA
    Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia.
    Illmer T; Babatz J; Pursche S; Stölzel F; Schuler U; Schaich M; Ehninger G
    Mycoses; 2011 Jul; 54(4):e143-7. PubMed ID: 20337942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.
    Störzinger D; Lichtenstern C; Swoboda S; Weigand MA; Hoppe-Tichy T
    Mycoses; 2008 Sep; 51 Suppl 2():52-7. PubMed ID: 18721332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
    Felton TW; Baxter C; Moore CB; Roberts SA; Hope WW; Denning DW
    Clin Infect Dis; 2010 Dec; 51(12):1383-91. PubMed ID: 21054179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
    Foo H; Gottlieb T
    Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
    [No Abstract]   [Full Text] [Related]  

  • 16. Posaconazole.
    Bhattacharya M; Rajeshwari K; Dhingra B
    J Postgrad Med; 2010; 56(2):163-7. PubMed ID: 20622401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole in newborns.
    Kohli V; Taneja V; Sachdev P; Joshi R
    Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
    Imai JK; Singh G; Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4063-6. PubMed ID: 15388482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.
    Corrigan VK; Legendre AM; Wheat LJ; Mullis R; Johnson B; Bemis DA; Cepero L
    J Vet Intern Med; 2016; 30(1):167-73. PubMed ID: 26566711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.